Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986458 in Relapsed/Refractory Non-Hodgkin Lymphoma
2023-506654-20-00Phase 2Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2024
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label trial of bms-986458 in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) (5 arms), sponsored by Bristol Myers Squibb. Planned start Feb 2024; status: authorised.
02
Drugs
bms-986458
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on 2023-506654-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506654-20-00.